Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
43.00
Dollar change
+0.34
Percentage change
0.80
%
Index- P/E- EPS (ttm)-2.73 Insider Own2.30% Shs Outstand75.37M Perf Week-1.80%
Market Cap3.24B Forward P/E- EPS next Y-3.29 Insider Trans-2.32% Shs Float73.69M Perf Month-13.36%
Income-182.39M PEG- EPS next Q-0.66 Inst Own94.83% Short Float3.56% Perf Quarter-6.11%
Sales0.00M P/S- EPS this Y-6.70% Inst Trans1.09% Short Ratio6.02 Perf Half Y22.75%
Book/sh12.31 P/B3.49 EPS next Y-12.95% ROA-21.22% Short Interest2.62M Perf Year24.85%
Cash/sh8.46 P/C5.08 EPS next 5Y8.90% ROE-22.12% 52W Range27.99 - 50.99 Perf YTD-6.64%
Dividend Est.- P/FCF- EPS past 5Y-10.87% ROI-19.45% 52W High-15.67% Beta1.15
Dividend TTM- Quick Ratio23.65 Sales past 5Y35.90% Gross Margin- 52W Low53.65% ATR (14)1.61
Dividend Ex-Date- Current Ratio23.65 EPS Y/Y TTM-33.48% Oper. Margin0.00% RSI (14)39.00 Volatility2.99% 4.06%
Employees259 Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin- Recom1.12 Target Price58.33
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-12.29% Payout- Rel Volume1.00 Prev Close42.66
Sales Surprise-100.00% EPS Surprise15.70% Sales Q/Q- EarningsFeb 29 AMC Avg Volume435.95K Price43.00
SMA20-4.16% SMA50-6.89% SMA2008.65% Trades Volume438,100 Change0.80%
Date Action Analyst Rating Change Price Target Change
Jan-04-24Initiated Citigroup Buy $62
Dec-08-23Initiated Robert W. Baird Outperform $63
Oct-24-23Resumed Cantor Fitzgerald Overweight
Apr-25-23Initiated Cantor Fitzgerald Overweight $58
Dec-14-22Initiated Goldman Buy $60
Dec-12-22Initiated Cowen Outperform
Nov-28-22Initiated Wells Fargo Overweight $50
Oct-19-22Initiated Raymond James Outperform $52
Aug-29-22Initiated BofA Securities Buy $45
Jul-21-22Initiated JP Morgan Overweight $55
Mar-12-24 04:01PM
Mar-08-24 11:55PM
Mar-05-24 04:01PM
Mar-02-24 08:37AM
Mar-01-24 08:35AM
04:34PM Loading…
Feb-29-24 04:34PM
04:13PM
04:01PM
Feb-22-24 04:01PM
Feb-21-24 10:08PM
Jan-23-24 08:36AM
Jan-19-24 09:55AM
Jan-08-24 08:00AM
Jan-03-24 08:30AM
Dec-05-23 01:31PM
04:16PM Loading…
Dec-04-23 04:16PM
Dec-02-23 12:01PM
Nov-29-23 10:51PM
04:03PM
Nov-28-23 11:17AM
Nov-27-23 04:28PM
12:19PM
07:30AM
07:09AM
07:00AM
04:21AM
Nov-09-23 05:14PM
04:03PM
Nov-08-23 04:28PM
04:01PM
04:01PM Loading…
Nov-01-23 04:01PM
Oct-31-23 02:58AM
Oct-09-23 04:15PM
Oct-06-23 08:30AM
Sep-14-23 04:01PM
Sep-12-23 04:30PM
Sep-04-23 08:30AM
Aug-31-23 10:16PM
04:01PM
Aug-29-23 10:21AM
Aug-11-23 09:55AM
Aug-09-23 05:15PM
04:09PM
04:01PM
08:03AM
Aug-08-23 04:01PM
Aug-02-23 04:01PM
Jul-23-23 11:44AM
Jun-06-23 04:35PM
May-31-23 04:01PM
May-11-23 04:01PM
May-09-23 05:15PM
04:13PM
04:01PM
May-04-23 10:00AM
03:52AM
May-03-23 04:01PM
May-02-23 04:01PM
10:01AM
Apr-24-23 08:00AM
Apr-21-23 04:01PM
Apr-18-23 08:15AM
Mar-22-23 04:01PM
Mar-06-23 01:07AM
Mar-04-23 07:48AM
Mar-02-23 05:31AM
Mar-01-23 05:25PM
04:01PM
Feb-22-23 04:01PM
Feb-08-23 04:01PM
Jan-20-23 05:25AM
Jan-09-23 08:00AM
Jan-04-23 04:01PM
Dec-02-22 08:30AM
Nov-30-22 04:01PM
Nov-29-22 03:17PM
Nov-12-22 07:29AM
Nov-09-22 04:30PM
04:05PM
Nov-08-22 05:35PM
04:01PM
Nov-07-22 08:30AM
Nov-03-22 08:30AM
Nov-01-22 08:25PM
04:01PM
Oct-19-22 01:36PM
Oct-06-22 03:14PM
Sep-01-22 04:01PM
Aug-29-22 07:14PM
Aug-15-22 07:24PM
Aug-12-22 07:40AM
Aug-09-22 05:15PM
04:01PM
Aug-08-22 08:30AM
Aug-02-22 04:01PM
Jul-22-22 06:20AM
Jul-11-22 04:01PM
Jun-27-22 02:11PM
09:28AM
Jun-23-22 04:10PM
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GAROFALO ELIZABETH A.DirectorMar 08 '24Option Exercise18.563,50064,9603,500Mar 11 08:09 PM
GAROFALO ELIZABETH A.DirectorMar 08 '24Sale45.692,09295,5830Mar 11 08:09 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationMar 07 '24Option Exercise9.858,64185,11416,824Mar 08 05:31 PM
GANNON STEVENDirectorMar 07 '24Sale46.2813,000601,6152,000Mar 08 05:28 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationMar 07 '24Sale46.287,137330,2908,398Mar 08 05:31 PM
AZAB MOHAMMADDirectorDec 19 '23Option Exercise9.854,32042,55274,225Dec 20 05:04 PM
PATOU GARYDirectorDec 13 '23Option Exercise9.5514,402137,48729,951Dec 15 05:38 PM
PATOU GARYDirectorDec 13 '23Sale39.2911,380447,08523,573Dec 15 05:38 PM
PATOU GARYDirectorDec 13 '23Sale41.057,598311,8984,902Dec 15 05:38 PM
Svoronos DawnDirectorAug 24 '23Sale38.7025,000967,50025,000Aug 24 04:33 PM
PIMSTONE SIMON N.DirectorJun 01 '23Option Exercise16.0354,318870,85551,000Jun 01 07:25 PM
PIMSTONE SIMON N.DirectorJun 01 '23Sale38.8231,7131,231,2476,000Jun 01 07:25 PM
PIMSTONE SIMON N.DirectorMay 31 '23Option Exercise14.8079,8351,181,87556,000Jun 01 07:25 PM
PIMSTONE SIMON N.DirectorMay 31 '23Sale38.7062,5262,420,0516,000Jun 01 07:25 PM
PIMSTONE SIMON N.DirectorMay 30 '23Sale39.2837,0061,453,67218,000Jun 01 07:25 PM
MORTIMER IANPRESIDENT & CEOMay 24 '23Option Exercise9.6069,340665,53648,592May 26 07:10 PM
MORTIMER IANPRESIDENT & CEOMay 24 '23Sale41.4131,6551,310,93124,213May 26 07:10 PM